Maravai LifeSciences (MRVI) Earnings Call Presentation

Business Overview - Maravai LifeSciences is targeting high-growth markets in mRNA, gene editing, cell and gene therapy, vaccines and biologics drug manufacturing[6] - The company provides critical assays for detecting impurities during biotherapeutics process development and commercial manufacturing[7] - Nucleic Acid Production accounted for 61% of total revenue in Q1 2025, with revenue of $29 million[19,48] - Biologics Safety Testing accounted for 39% of total revenue in Q1 2025, with revenue of $18 million[41,48] - 96% of top 25 global biopharmaceutical companies ranked by R&D spend are Maravai customers[10,13,14] Financial Highlights - The company's cash position is $285 million as of Q1 2025[51] - Long-term gross debt is $298 million as of Q1 2025[51] - Adjusted EBITDA for Biologics Safety Testing in Q1 2025 was $18 million, representing a 70% adjusted EBITDA margin[48] - Adjusted EBITDA for Nucleic Acid Production in Q1 2025 was ($9 million), representing a (31%) adjusted EBITDA margin[48] - Adjusted net loss was $(20436) thousand, and adjusted fully diluted loss per share was $(008) in Q1 2025[64] Growth and Pipeline - CleanCap® is used in preclinical programs (70% of total programs) and clinical programs (30% of total programs)[28] - Clinical programs using CleanCap® have increased by 15% year-over-year[28]